65,437 trials
Metastatic Breast Cancer
Primary: The Safety of dHER2+AS15 ASCI When Administered in Combination With Lapatinib Measured by Occurrence of Severe Toxicities (According to CTCAE, Version 3.0) — 0…
Antisocial Personality Disorder · Substance Use Disorder
Primary: Risk for Criminal Recidivism (Criminal Thinking) — 53.66; 53.30 score on a scale — p=>0.05
Gastric Cancer
Primary: Overall Survival — 16.0; 15.1 Months — p=0.039
Obesity
Primary: Change in Grip Strength — 1.2 kg
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population. — 3.9; 39.4…
Smoking Cessation
Primary: Rate of Participant Retention — 23; 29; 18; 10 Participants
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Asthma · COPD · Interstitial Lung Disease
Primary: FEV1 — 3.03; 2.32; 3.18; 2.76 L
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
HIV/AIDS · Medication Adherence
Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication
Heart Failure
Primary: Blood Flow — 300; 275 ml/min
Walled Off Pancreatic Necrosis
Primary: Number of Participants With Resolution of WON With Endoscopic Drainage — 39 Participants
Heart Failure, Congestive
Primary: Ejection Fraction — 33; 30; 25 % of blood ejected with each beat
Colonoscopy
Primary: Percentage of Participants Who Complete Colonoscopy Using Virtual Reality and no Pharmacological Rescue — 26 Participants
Pain
Primary: Short-Form McGill Pain Questionnaire (Version 2) Total Score Difference From Baseline — -1.85; -0.05 score on a scale — p=0.003